{
    "clinical_study": {
        "@rank": "114379", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo arm"
            }, 
            {
                "arm_group_label": "ASLAN003", 
                "arm_group_type": "Other", 
                "description": "Active drug"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a single-centre, placebo-controlled, randomised, double-blind study to evaluate the\n      safety and tolerability of single ascending doses (SAD) and multiple ascending doses (MAD)\n      of ASLAN003 in healthy  subjects"
        }, 
        "brief_title": "Phase 1, Randomised Double Blinded Placebo Controlled Study of ASLAN003", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "detailed_description": {
            "textblock": "This is a single-centre, placebo-controlled, randomised, double-blind study involving SAD\n      and MAD of ASLAN003 in healthy subjects.\n\n      The study is divided into two parts:\n\n        -  Part A:  SAD cohorts and 1 cohort to assess food effect of ASLAN003 PK.\n\n        -  Part B:  MAD cohorts with one cohort being of healthy elderly subjects.\n\n      There will be a sentinel pair of subjects for each of SAD Cohorts 1, 2 and 3 who will be\n      dosed first and then the same dose will be given to the rest of the subjects in the\n      respective cohorts.\n\n      In addition, 8 subjects will receive ASLAN003 under both fed and fasted conditions"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The inclusion criteria for all subjects are as follows:\n\n          -  are capable of understanding and complying with the requirements of the study and\n             have signed the informed consent form (ICF);\n\n          -  are able to communicate well with the Investigator, and understand and comply with\n             the requirements of the study;\n\n          -  male subjects aged between 21 and 50 years, inclusive (Part A and Cohorts 5, 6 and 7\n             of Part B only); male subjects and female subjects of non childbearing potential aged\n             \u226555 years (Cohort 8 of Part B only);\n\n          -  body mass index (BMI) in the range of 18 to 30 kg/m2, inclusive;\n\n          -  healthy, as determined by pre study medical history, physical examinations, vital\n             sign measurements, electrocardiogram (ECG; 12 lead reporting RR, PR, QRS, corrected\n             QT [QTc] and QT interval corrected for heart rate using Fridericia's formulas [QTcF])\n             recordings with no evidence of clinically relevant medical disorders based on the\n             opinion of the Investigator;\n\n          -  whose out-of-normal range clinical laboratory test results are not clinically\n             relevant and are acceptable to the Investigator;\n\n          -  male subjects must be willing to use barrier contraception during sexual intercourse,\n             i.e. condoms, even if their partners are post-menopausal, surgically sterile or are\n             using accepted contraceptive methods, from the first day of dose administrations\n             until 3 months after the last dose administration;\n\n        Exclusion Criteria:\n\n          -  The exclusion criteria for all subjects are as follows:\n\n          -  have participated in a study involving another investigational device or drug study\n             within 90 days prior to randomisation in this study;\n\n          -  history of drug hypersensitivity reactions or hypersensitivity to drugs chemically\n             related to the IP;\n\n          -  history or evidence of a clinically significant disorder, condition or disease\n             (including, but not limited to, cardiopulmonary, oncologic, autoimmune, immunogenic,\n             renal, metabolic, haematological or psychiatric), that, in the opinion of the\n             Investigator, would pose a risk to subject safety or interfere with the study\n             evaluation, procedures or completion;\n\n          -  existence of any surgical or medical condition which, in the judgement of the\n             Investigator, may interfere with the absorption, distribution, metabolism or\n             excretion of the IP;\n\n          -  clinically significant history or evidence of any active or suspected bacterial,\n             viral, fungal or parasitic infection within the 30 days prior to randomisation (e.g.\n             common cold, viral syndrome, flu-like symptoms, etc.);\n\n          -  active or recent history (within 30 days prior to randomisation) of acute viral\n             infection of the skin (e.g. Herpes simplex, Molluscum contagiosum);\n\n          -  active or history of psoriasis, or a first-degree relative with active or history of\n             psoriasis;\n\n          -  known history or evidence of active or latent tuberculosis infection (e.g. positive\n             tuberculin skin test showing induration >5 mm or positive tuberculin blood test) in\n             absence of previous Bacillus Calmette Guerin vaccination, or recent exposure (within\n             6 months prior to randomisation in this study) to an individual with active\n             tuberculosis or with intention to travel to a country with a high risk of\n             tuberculosis during the study period (including the follow up period);\n\n          -  history of autoimmune disease including but not limited to lupus, rheumatoid\n             arthritis, autoimmune thyroid disease and immune thrombocytopenia;\n\n          -  with QT or QTcF values higher than 450 ms at screening;\n\n          -  history of regular alcohol consumption (within 6 months prior to randomisation in\n             this study), defined as: an average weekly intake of greater than 21 units or any\n             average daily intake of greater than 3 units.  One unit is equivalent to a half pint\n             (220 mL) of beer or 1 (25 mL) measure of spirits or 1 glass (125 mL) of wine;"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01992367", 
            "org_study_id": "ASLAN003-001"
        }, 
        "intervention": {
            "arm_group_label": [
                "Placebo", 
                "ASLAN003"
            ], 
            "description": "This is a single-centre, placebo-controlled, randomised, double-blind study involving SAD and MAD of ASLAN003 in healthy subjects.", 
            "intervention_name": "ASLAN003 ACTIVE", 
            "intervention_type": "Drug", 
            "other_name": "ASLAN 003 , LAS186323"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 19, 2013", 
        "location": {
            "contact": {
                "email": "edmund_jd_lee@nuhs.edu.sg", 
                "last_name": "Prof. Edmund Jon Deoon Lee Prof. Edmund Jon Deoon Lee, MD", 
                "phone": "65 6850 2600"
            }, 
            "facility": {
                "address": {
                    "city": "Singapore", 
                    "country": "Singapore"
                }, 
                "name": "Changi General Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Singapore"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Randomised, Double Blind, Placebo Controlled, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of ASLAN003 in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Changi General Hospital", 
            "last_name": "Prof Edmund Lee Lee, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Singapore: Health Sciences Authority", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety assessments will include 12 lead ECGs, physical examiniation, vital signs measurements, pulse rate, RR, body temperature, clinical laboratory assessments and recording of adverse events", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01992367"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Aslan Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aslan Pharmaceuticals", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}